Fort Myers-based oncology testing services company Neo Genomics announced Chris Smith will retire as CEO and board member effective April 1. Tony Zook, an independent board member since 2023, will assume the role of CEO at that time, company officials said.

Since Smith was appointed CEO in August 2022, his strategic vision and execution resulted in eight consecutive quarters of double-digit revenue growth and a recovery from negative $48 million of Adjusted EBITDA in 2022 to positive $37-$40 million of Adjusted EBITDA expected in 2024. Smith deployed a patient and customer-centric strategy, which enabled NeoGenomics to serve more than 1.5 million cancer patients during his tenure. He will remain with the company as an advisor throughout the transition.

Zook is a partner with Lucius Partners, a specialized health care consultancy providing financial, strategic, product development and operational insights to emerging biopharmaceutical and medical device companies across multiple therapeutic areas. Prior to his consulting work and role as CEO of Innocoll Pharmaceuticals, Zook was executive vice president of global commercial operations at AstraZeneca, where he held global profit and loss responsibility for all of the company’s brands and markets, representing over $30 billion in revenues.